Almac Diagnostics Multi Year License Agreement with GeneGo
News Jan 02, 2007
The multiple-year agreement will allow Almac Diagnostics' scientists in the UK and US to use MetaCore in the development of microarray-based products for the diagnosis and treatment of cancer.
Almac Diagnostics' Genomic Services division that delivers genomic services to academic, biotech and pharmaceutical customers will also use MetaCore.
Almac values the completeness and quality of content coverage in MetaCore from signaling ligands to core metabolic pathways, its interface and automated analysis workflows.
"We compared several platforms before we finally decided on GeneGo. MetaCore has broad and deep, high quality content coverage, which was important to us. Furthermore its ability to work with mixed IDs is critical for our internal R&D work and service offerings based on our unique DSA™ (patent pending) research tools," said Dr. Vitali Proutski, Bioinformatics Manager at Almac Diagnostics.
“We were also very impressed by GeneGo's responsiveness and strong customer support which we feel is vital in relationships with our partners."
"We are very pleased to welcome Almac Diagnostics as a new GeneGo customer. Our experience with them during the thorough evaluation was very positive, with constant communication between Almac Diagnostics and GeneGo scientists," said Julie Bryant, Vice President of Business Development at GeneGo.
"Our products are gaining momentum in clinical diagnostics, both on the development side and among practitioners. Almac combines both as a highly reputable, scientific oriented new generation CRO."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.